Chronic Liver Disease and Cirrhosis

The answer first

Cirrhosis is the late stage of hepatic fibrosis in which regenerative nodules and fibrous septa distort the hepatic architecture and produce the structural and haemodynamic consequences of chronic liver disease. It is not a single disease — it is the common endpoint of many chronic liver injuries. The single most important concept for the exam is that cirrhosis is staged, and the stage drives everything. [1]

Cirrhosis has four clinical stages, and the patient moves in one direction without reversal of the underlying cause: [1]

1. Compensated without varices — portal pressure below the threshold for clinically significant portal hypertension (CSPH).
2. Compensated with varices — CSPH present (HVPG greater than or equal to 10 mmHg), no decompensation.
3. Decompensated — first decompensating event: ascites, variceal bleed, encephalopathy or jaundice.
4. Late decompensated — recurrent or multiple decompensating events, sepsis, organ failure. [1]

DCE trap: The biggest management pivot in hepatology is the move from compensated to decompensated cirrhosis. In the compensated phase you prevent the first decompensation (treat the cause, start a non-selective beta-blocker if CSPH). In the decompensated phase you treat complications and assess for transplant. Name the stage first in every long case. [1]

---

References8Show ledgerHide ledger

1. [1]Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial Lancet, 2019.PMID 30910320
2. [2]García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding N Engl J Med, 2010.PMID 20573925
3. [3]de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension J Hepatol, 2022.PMID 35120736
4. [4]Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med, 1999.PMID 10432325
5. [5]Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy N Engl J Med, 2010.PMID 20335583
6. [6]Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome N Engl J Med, 2021.PMID 33657294
7. [7]Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature J Hepatol, 2023.PMID 37364790
8. [8]Sarin SK, Wadhawan M, Agarwal S, et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding Am J Gastroenterol, 2005.PMID 15784021